Skip to main content
Premium Trial:

Request an Annual Quote

Dennis Gilbert, Joseph Shaw, Thomas Watkins, Frank Douglas, Paul Lucas, Neil M. Reid, Michael Mueller, Arden Bement, Jr., and Randall Murch


Dennis Gilbert has become CSO and vice president for research of Applied Biosystems, as well as vice president of Applera, the company said in an SEC filing this week. He joined Applera in 1994 as a research scientist and was most recently ABI’s vice president for advanced research and technology.

Joseph Shaw has been appointed as CEO and member of the board of directors of OpGen. Shaw comes to the position from a presidency at Bank On a Cure, and from AusAmerican Group, where he also served as president.

Thomas Watkins has become CEO of Human Genome Sciences, succeeding William Haseltine, who retired last month, HGS said this week. He will also join the company’s board of directors. Watkins joins HGS from TAP Pharmaceutical Products, a company jointly owned by Abbott Laboratories and Takeda Pharmaceutical, where he was president. Watkins holds an MBA from the University of Chicago Graduate School of Business and a bachelor’s degree from the College of William and Mary.

Frank Douglas has been appointed to fill a vacancy on the board of directors of Gene Logic. Until his recent retirement, Douglas was executive vice president, drug innovation & approval and CSO of Aventis Pharma AG, where he oversaw Aventis' worldwide pharmaceutical research and development activities and was a member of the board of management of parent firm Aventis SA.

TM Bioscience has appointed Paul Lucas chairman of the board. Lucas is currently president and CEO of GlaxoSmithKline Canada and has served as an independent director of TM since 2002. The Toronto-based firm also appointed Neil M. Reid vice chairman and Michael Mueller as a director. Reid has served as a director of TM since 2000 and is currently senior vice president of Protana. Mueller currently serves as president and CEO of MDS Capital.

Arden Bement, Jr., has been appointed by President Bush as the 12th director of the National Science Foundation. He has served as acting director of the agency since Feb. 22. The Senate confirmed Bement on Nov. 20. He has served as director of the National Institute of Standards and Technology since 2001, but resigned that post concurrent with his appointment as NSF director. Bement's term as NSF director lasts six years.

Randall Murch has been named associate director for research program development at Virginia Tech, where he will be responsible for strategic planning, as well as initiating and fostering research relationships between federal, state and local agencies, Virginia Tech, and centers that focus on life science and bio-security. As part of his duties, Murch will work closely with The Institute for Genomic Research, which has a recently formed strategic relationship with the university. He joins Virginia Tech from the Institute for Defense Analyses.

Filed under

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.